More People Die After Smoking Drugs Than Injecting Them
NEW YORK — Smoking has surpassed injecting as the most common way of taking drugs in U.S. overdose deaths, a new government study suggests.
The Centers for Disease Control and Prevention called its study published Thursday the largest to look at how Americans took the drugs that killed them.
[time-brightcove not-tgx=”true”]
CDC officials decided to study the topic after seeing reports from California suggesting that smoking fentanyl was becoming more common than injecting it. Potent, illicit versions of the painkiller are involved in more U.S. overdose deaths than any other drug.
Some early rese...
Source: TIME: Health - February 15, 2024 Category: Consumer Health News Authors: MIKE STOBBE/AP Tags: Uncategorized healthscienceclimate wire Source Type: news
North Carolina biotech inks $30M deal to expand its global pipeline
A biotechnology firm in Durham is betting millions on a potential treatment for hepatitis B. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 15, 2024 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
Hepatitis A Exposure Response and Outbreak Prevention in a Large Urban Jail - Los Angeles County, California, May-July 2023
This report describes Correctional Health Services and LA County Jail's response to a confirmed case of Hepatitis A in a person who is incarcerated. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - February 15, 2024 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Source Type: news
Gilead Sciences CEO on company ’s evolution and commitment to the Bay Area
Much has changed since Daniel O ’Day, chairman and CEO, arrived at Gilead Sciences in 2019. The company has grown considerably and expanded on its long-standing leadership in antiviral therapies to include a focus on cancer medicines. Today the Foster City-based company is the second-largest biotech employer in the Bay Area, and according to a Bay Area Council report, it created an estimated economic impact of $22.1 billion in 2020 alone. It has more than 25 marketed therapies for HIV, cancer, hepatitis,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 12, 2024 Category: Biotechnology Authors: Gilead Sciences Source Type: news
CDC: Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) is allowing an additional 30 days for comments on a proposed information collection project titled "Formative Research and Tool Development." This information collection request is designed to allow CDC's National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) to conduct formative research information collection activities used to inform many aspects of surveillance, communications, health promotion, and research project development for NCHHSTP's four priority diseases: HIV/AIDS, sexually transmitted diseases/infections (STD/STI), viral hepatitis, tube...
Source: Federal Register updates via the Rural Assistance Center - February 9, 2024 Category: Rural Health Source Type: news
World Cancer Day 2024
Cancer is a major contributor to global mortality, causing about 1 in every 6 deaths and affecting nearly every household (1). Globally, there were an estimated 20 million new cases of cancer and 9.7 million deaths from cancer in 2022. The cancer burden will increase by about 77% by 2050, further straining health systems, people and communities (2).
In the WHO Eastern Mediterranean Region alone, more than 788 000 people were diagnosed with cancer in 2022. This number is projected to double to reach 1.57 million cases by 2045, because of population growth and, more importantly, the high prevalence of cancer risk factors in...
Source: WHO EMRO News - February 1, 2024 Category: Middle East Health Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news
The U.S. Hasn ’ t Seen Syphilis Numbers This High Since 1950
NEW YORK — The U.S. syphilis epidemic isn’t abating, with the rate of infectious cases rising 9% in 2022, according to a new federal government report on sexually transmitted diseases in adults.
But there’s some unexpected good news: The rate of new gonorrhea cases fell for the first time in a decade.
[time-brightcove not-tgx=”true”]
It’s not clear why syphilis rose 9% while gonorrhea dropped 9%, officials at the U.S. Centers for Disease Control and Prevention said, adding that it’s too soon to know whether a new downward trend is emerging for the latter.
They are most fo...
Source: TIME: Health - January 30, 2024 Category: Consumer Health News Authors: Mike Stobbe/AP Tags: Uncategorized healthscienceclimate wire Source Type: news
South Sudan: MSF Launches Mass Vaccination Campaign Amid Deadly Hepatitis E Outbreak
[MSF] Juba - In response to a deadly hepatitis E outbreak in South Sudan, MSF has launched a vaccination campaign in collaboration with the Ministry of Health to provide protection to women and girls of reproductive age, who are at greatest risk of death from the disease. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 30, 2024 Category: African Health Tags: Aid and Assistance East Africa Health and Medicine NGOs and Civil Society South Sudan Source Type: news
The Breakthrough Drug Whose Full Promise Remains Unrealized The Breakthrough Drug Whose Full Promise Remains Unrealized
With its approval in 2013, sofosbuvir revolutionized treatment for hepatitis C, but the goal of eliminating this disease is still decades away.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 22, 2024 Category: Gastroenterology Tags: Gastroenterology Commentary Source Type: news
IIL launches first indigenous Hepatitis A vaccine
Priced at ?2,150 per dose, it is a two-dose vaccine in which the first dose is administered at above 12 months of age and the second dose is given at least after 6 months of the first dose. The vaccine is also recommended for individuals who are at risk of exposure or travel to the regions with high hepatitis A prevalence. In addition to this people with occupational risk of infection and suffering from chronic liver diseases also need Hepatitis A vaccination. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 19, 2024 Category: Pharmaceuticals Source Type: news
Emergency Department Use Up for Alcohol-Associated Hepatitis
THURSDAY, Jan. 18, 2024 -- There was an overall increase in emergency department utilization rates for alcohol-associated hepatitis (AH) from 2016 to 2019, according to a study published online Jan. 9 in Alcohol: Clinical& Experimental... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2024 Category: Pharmaceuticals Source Type: news
Drug induced autoimmune hepatitis: an unfortunate case of herbal toxicity from Skullcap supplement: a case report - Thakral N, Konjeti VR, Salama FW.
BACKGROUND: The surge in traditional herbal dietary supplement (HDS) popularity has led to increased drug-induced liver injuries (DILI). Despite lacking evidence of efficacy and being prohibited from making medical claims, their acceptance has risen over s... (Source: SafetyLit)
Source: SafetyLit - January 17, 2024 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
What The Hepatitis C Crisis Says About The U.S. Healthcare System
There has been a cure for Hepatitis C since 2014, yet nearly 4 million Americans are living with the viral infection, according to American Liver Foundation. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 16, 2024 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
